NCT04991922 BostonGene-Integrated Genomic Registry (BIGR)
| NCT ID | NCT04991922 |
| Status | Recruiting |
| Phase | — |
| Sponsor | BostonGene |
| Condition | Malignancy |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2021-07-01 |
| Primary Completion | 2031-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2021-07-01 with a primary completion date of 2031-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
Eligibility Criteria
Inclusion Criteria: 1. Suspected or confirmed malignancy 2. Planned comprehensive genomic (\> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing 3. Baseline demographics and treatment information available 4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment. 5. Signed informed consent to participate in the study. 6. Living in the United States at the time of enrollment Exclusion Criteria: Life expectancy \< 3 months
Contact & Investigator
Nathan Fowler
PRINCIPAL INVESTIGATOR
BostonGene
Frequently Asked Questions
Who can join the NCT04991922 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04991922 currently recruiting?
Yes, NCT04991922 is actively recruiting participants. Contact the research team at nathan.fowler@bostongene.com for enrollment information.
Where is the NCT04991922 trial being conducted?
This trial is being conducted at Waltham, United States.
Who is sponsoring the NCT04991922 clinical trial?
NCT04991922 is sponsored by BostonGene. The principal investigator is Nathan Fowler at BostonGene. The trial plans to enroll 100,000 participants.